Company intelligence / Profile preview
Immunophotonics
Saint Louis, Missouri, United Statesimmunophotonics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Clinical-stage biotech developing IP-001 to reduce cancer recurrence through immune activation. Phase1b trials demonstrated safety and early anti-tumor activity. Currently in Phase1b/2a trials (NCT05688280, NCT03993678) and preparing Phase2/3 pivotal trial[1][3].
- Therapeutic areas
- Oncology
- Modalities
- Intratumoral immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
partner_name:Johnson & Johnson Enterprise Innovation Inc., focus:Radiation-based tumor destruction combinations[1]partner_name:Cardiovascular and Interventional Radiological Society of Europe (CIRSE), focus:Phase2/3 trial design and implementation[3]
Beyond the preview
Go deeper on Immunophotonics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunophotonics.